News

The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. The submission of

These methods further strengthen ViaCyte’s intellectual property platform, providing alternative ways to produce pancreatic progenitor and endocrine cells that have potential for use in cell replacement therapies. Pancreatic

Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme, a Sanofi company. Cerdelga was approved by the U.S. Food and Drug

The deal, funded through a combination of cash, debt and equity, includes the purchase of Omega’s equity for €2.48bn and the assumption of €1.1bn in debt. The acquisition

Currently, the company is evaluating the efficacy and safety of SD-809 to treat chorea associated with this disorder in a Phase III registration clinical trial and is scheduled

Myalept is an orphan product indicated to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy, a rare disease associated with the loss of

MM-141 is a tetravalent bispecific antibody that blocks tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3), which activate a major cellular signaling pathway that

DRP, which is a highly validated systems-biology-based biomarker platform, has been developed by MPI and it is useful for identifying likely responding patients for targeted enrollment of cancer

The trial is designed to assess ThermoDox in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. ThermoDox